A once daily drug combination of sofosbuvir-velpatasvir for 12 weeks resulted in sustained eradication of several genotypes of the hepatitis C virus in 99% of patients in a clinical trial, according to a study in The New England Journal of Medicine. Read more and read the study abstract.
Get your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.
NurseLine Newsletter
*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.
